Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)
11 févr. 2019 07h30 HE
|
Avenue Therapeutics
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a Fortress Biotech (NASDAQ: FBIO) company, today announced the completion of the first stage closing...
Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain
19 déc. 2018 08h00 HE
|
Avenue Therapeutics
NEW YORK, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous...
Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
14 nov. 2018 16h30 HE
|
Avenue Therapeutics
NEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous...
InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.
13 nov. 2018 06h30 HE
|
Avenue Therapeutics
Upon first stage closing, InvaGen Pharmaceuticals Inc., a Cipla subsidiary (“InvaGen”), to acquire shares representing a 33.3% stake in Avenue Therapeutics, Inc. (“Avenue”) on a fully diluted basis...
Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
14 août 2018 07h30 HE
|
Avenue Therapeutics
Company reported positive Phase 3 data in patients with post-surgical pain following bunionectomy Initiation of second pivotal Phase 3 trial expected in the second half of 2018 NEW YORK, Aug. 14,...
Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference
19 juin 2018 08h30 HE
|
Avenue Therapeutics
NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous...
Avenue Therapeutics to Host Key Opinion Leader Call on Intravenous (IV) Tramadol for the Management of Postoperative Pain
06 juin 2018 08h30 HE
|
Avenue Therapeutics
NEW YORK, June 06, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain
21 mai 2018 06h30 HE
|
Avenue Therapeutics
IV tramadol achieved primary and key secondary endpoints, as well as a clear dose response Initiation of second pivotal Phase 3 trial planned for third quarter of 2018 Management to host conference...
Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
03 mai 2018 07h30 HE
|
Avenue Therapeutics
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol
28 mars 2018 08h00 HE
|
Avenue Therapeutics
NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...